Donald Patrick, PhD, MSPH

Professor and Director
Seattle Quality of Life Group
University of Washington
Seattle, WA, USA


Donald Patrick, Professor of Health Services at the University of Washington, also holds appointments in the Departments of Epidemiology, Sociology, Rehabilitation Medicine and Pharmacy. He is a Full Member of the Fred Hutchinson Cancer Research Center.

Dr. Patrick directs the Seattle Quality of Life Group (www.seaqolgroup.org) and the Center for Disability Policy and Research (www.depts.washington.edu/cdpr) and with faculty at the University and Fred Hutchinson, directs the Biobehavioral Cancer Prevention and Control Training Program.

Over the past four decades, Dr. Patrick has published widely on the assessment of health status and quality of life. He has developed many preference-based and descriptive generic and condition-specific measures of QOL, often with cross-cultural applications, including the Irritable Bowel Syndrome Quality of Life Instrument. He Co-Chairs the Translation and Cultural Adaptations Special Interest Group of the International Society for Quality of Life Research. He spent a sabbatical year in Lyon, France working on cross-cultural adaptation of health outcome instruments. He is a member of the Scientific Advisory Committee for the MAPI Research Institute.

He is currently applying outcomes assessment in adolescent health and a wide variety of chronic diseases including obesity, cystic fibrosis, deafness and hard of hearing, HIV, and diabetes. Much of his research work is directed toward promoting the health and quality of life of people with stigmatizing conditions arising from birth or during the life course. He was the Inaugural President of the International Society for Quality of Life Research. Dr. Patrick is a member of the Institute of Medicine, National Academy of Sciences.

Dr. Patrick was a Special Government Employee to the FDA working on the guidance for use of patient-reported outcomes in the evaluation of medical products for approval and promotion of medical products. He has also been a special consultant to the Inter-Agency Workgroup on Health Outcomes Assessment of the Public Health Service in assisting with the use of health outcomes assessment at the National Institutes of Health, Centers for Disease Control and Prevention, and National Center for Health Statistics. He currently is a Principal Investigator of the NIH Roadmap Initiative PROMIS to develop item banks and instruments based on modern test theory in relation to patients infected with HIV. He serves on numerous advisory committees and study sections in the US and abroad. He has authored expert reports for the filing of drug approvals and promotion with the FDA and with the European Medicine Evaluations Agency. He is an author of numerous publications, a book entitled Health Status and Health Policy published by Oxford University Press and a recent book with Richard Deyo on Hope or Hype: The Obession with Medical Advance and the High Cost of False Promises funded by a Robert Wood Johnson Health Policy Investigator Award. He consults widely with Industry and Government on the use of health status and quality of life assessments.